PERSPECTIVE THERAPEUTICS, INC. Public Float
PERSPECTIVE THERAPEUTICS, INC. (CATX) had Public Float of $212.87 million as of 2025-06-30, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Cover Page
dei:EntityPublicFloat · last filed 2026-03-16
- 2025-06-30: Entity Public Float $212.87M.
- 2024-06-28: Entity Public Float $551.72B.
- 2023-06-30: Entity Public Float $186.42M.
- 2022-06-30: Entity Public Float $43.56M.
| Period end | Entity Public Float |
|---|---|
| 2025-06-30 | $212.87M 10-K · filed 2026-03-16 |
| 2024-06-28 | $551.72B 10-K/A · filed 2025-03-28 |
| 2023-06-30 | $186.42M 10-K · filed 2024-03-28 |
| 2022-06-30 | $43.56M 10-KT · filed 2023-05-01 |
| 2021-12-31 | $54.85M 10-K · filed 2022-09-28 |
| 2020-12-31 | $38.73M 10-K · filed 2021-09-27 |
| 2019-12-31 | $41.41M 10-K · filed 2020-09-25 |
| 2018-12-31 | $20.08M 10-K · filed 2019-09-27 |
| 2017-12-31 | $22.04M 10-K · filed 2018-09-26 |
| 2016-12-31 | $31.91M 10-K · filed 2017-09-28 |
| 2015-12-31 | $51.30M 10-K · filed 2016-09-09 |
| 2014-12-31 | $79.78M 10-K · filed 2015-09-14 |
| 2013-12-31 | $19.03M 10-K · filed 2014-09-29 |
| 2012-12-31 | $27.00M 10-K · filed 2013-09-30 |
| 2011-12-31 | $19.35M 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |